Dioxo molybdenum complexes of general formula Tp*MoO(2)(S-p-RC(6)H(4)) (1), where Tp* = hydrotris(3,5-dimethyl-1-pyrazolyl)borate and R = OMe, Me, SMe, NHCOMe, H, Cl, CF(3), NO(2), were reacted with trimethyl phosphine (PMe(3)) to convert into complexes of general formula Tp*MoO(S- p-RC(6)H(4))(OPMe(3)) (2) (where R = OMe, Me, SMe, H, Cl, and CF(3)). These complexes were isolated and characterized by NMR, IR, UV/vis, and single crystal X-ray crystallography. Electronic and NMR spectra, as well as redox potentials vary as a function of substituent on the thiophenolato ligand. When viewed entirety of the oxygen atom transfer (OAT) reactivity, the reaction of Tp*MoO(2)(S-p-RC(6)H(4)) with PMe(3) shows a biphasic behavior, indicating the formation of at least one intermediate. The kinetics of the both steps, that is, the formation of the phosphoryl intermediate and the formation of the solvent coordinated species have been investigated by UV-vis spectroscopy. The first step follows a second order process, first order with respect to both the complex and PMe(3), and the overall second order rate constants at 25 degrees C range from 98.2 (+/-0.01) x 10(-2) M(-1) s(-1) (for R = OMe) to 223.0 (+/-0.20) x 10(-2) M(-1) s(-1) (for R = CF(3)); activation parameters were in the ranges DeltaH(++) = 49.3(+/-4.1) kJ x mol(-1) (for R = OMe) to 34.0 (+/-7.5) kJ x mol(-1) (for R = CF(3)), DeltaS(++) = -154.0 (+/-14.2) J x mol(-1) x K(-1) (for R = OMe) to -184.3 (+/-26.1) J x mol(-1) K(-1) (for R = CF(3)), and DeltaG(++) = 95.0 kJ x mol(-1) (for R = OMe) to 88.7 kJ x mol(-1) (for R = CF(3)). Formation of the acetonitrile complex from the phosphoryl complex follows a first order process with respect to the complex. The first order rate constants at 25 degrees C range from 3.60 (+/-0.01) x 10(-4) sec(-1) (for R = OMe) to 6.32 (+/-0.11) x 10(-4) sec(-1) (for R = CF(3)), and the enthalpy of activation and entropy of activation show variation; DeltaH(++) = 62.5 (+/-2.2) to 67.8 (+/-1.0) kJ x mol(-1), DeltaS(++) = -82.5 (+/-3.3) to -101.3 (+/-7.5) J x mol(-1) x K(-1), but the free energy of activation remains constant DeltaG(++) approximately 92 (+/-1) kJ x mol(-1). Large entropies of activation associated with both steps are consistent with associative transition states. The comparable magnitude of the activation energy of the two steps underscores the difficulty in identifying the rate-limiting step in the overall OAT reaction. The first step, however, is more sensitive toward the substituent effects than the second step. Therefore, a change in the substituent can play an important role in deciding the rate-limiting step involved in a two-step OAT reaction.

The oxygen atom transfer reactivity of Tp( *)MoO(2)(SPh) (1) (where Tp( *)=hydrotris-(3,5-dimethylpyrazol-1-yl)borate) with trimethyl phosphine (PMe(3)) has been investigated. The reaction proceed through a diamagnetic phosphoryl intermediate complex, Tp( *)MoO(SPh)(OPMe(3)) (2), which has been isolated and characterized by IR, NMR, UV-visible spectroscopy, and mass spectrometry. The molecular structure of 2 has been determined by X-ray crystallography. The complex crystallizes in monoclinic (P2(1)/n) space group, a=19.81 (1)A, b=11.1 (4)A, c=18.416 (5)A, beta=121.2 (3) degrees , V=3463.8 (25)A(3) with Z=4. In acetonitrile, complex 2 exchanges its phosphoryl ligand with a solvent molecule resulting in Tp( *)MoO(SPh)(MeCN) (3), which has been isolated and also characterized spectroscopically and by X-ray crystallography. Compound 3 crystallizes in triclinic (P1 ) space group, a=10.159 (6)A, b=18.563 (5)A, c=7.986 (3)A, alpha=96.22 (3) degrees , beta=121.2 (3) degrees , gamma=84.64 (3) degrees , V=1452.4 (11)A(3) with Z=2. The electronic structures of the complexes have been investigated by density functional theory and the redox chemistry has been investigated by cyclic and differential pulse voltammetry. In acetonitrile, complex 2 spontaneously transforms to complex, 3 at a rate of 5.6x10(-4)s(-1).

Coordination by at least four sulfur donors to an embedded molybdenum center has been found to be a common feature in the crystal structures of many mononuclear molybdenum enzymes. In an effort to model embedded molybdenum centers, we have synthesized dendritic thiolate ligands and their oxo-molybdenum complexes containing a [Mo(V)OS(4)](-) core. These compounds have been isolated in pure form as blue solids or gummy materials, and the molecular nature of these compounds has been confirmed by electrospray ionization mass spectrometry and infrared, electron paramagnetic resonance, and UV-vis spectroscopies. The dendritic complexes exhibit little variation in their broad S --> Mo charge transfer band (lambda(max) approximately 600 nm; epsilon approximately 6000 M(-)(1) cm(-)(1)), Mo=O vibration energy (941-943 cm(-)(1)), and EPR g-values (g( parallel ) approximately 2.02; g( perpendicular ) approximately 1.98; g(av) approximately 1.99). The spectroscopic data confirm the integrity of the square pyramidal [Mo(V)OS(4)](-) core with little geometric distortions, suggesting that the electronic structure at the metal center is not perturbed by the ligand architecture. The electronic structure of these complexes, calculated by the density functional theory, demonstrates a similar composition of the HOMO. In complexes 6 and 7a, the energy of the HOMO orbital might be modulated by the difference in the electronic structure of the ligands. The Mo(V/IV) reduction potentials vary as a function of the dielectric constant and the donor number of the solvent. The kinetics of the reduction is influenced by the reorganization of the geometry and the encapsulating effect. We suggest that protein structure imposed microenvironments may control the dielectric properties and hence the redox properties of the metal center in many metallobiomolecules.

No abstract

Dioxo-Mo VI complexes of general formula Tp*MoO 2 (p-SC 6 H 4 Dn) (6a-6c) (where Tp* = hydrotris (3,5-dimethyl-pyrazol-1-yl)borate and Dn= dendritic unit) have been synthesized and characterized by spectroscopy and mass spectrometry. 1 H NMR spectra of the metal complexes indicate that the C s local symmetry about the metal core does not change by the incorporation of dendritic functionality at the thiophenolato ring. Electrochemical data show ∼20 mV change in the redox potential in the complexes with dendritic ligands suggesting a very small perturbation in the redox orbital, which is also supported by small changes in the electronic spectra. The peak-to peak separation (ΔE p ) increases from 125 mV in 6(a) to 240 mV in 6(c), suggesting sluggish electron transfer in molecules with larger dendritic ligands.

Epidermal growth factor receptor (EGFR) vIII is a mutated EGFR that is frequently overexpressed in glioblastomas and implicated in response to receptor tyrosine kinase inhibitors. In this study, we investigate the effect of ZD6474 (ZACTIMA, vandetanib), a dual inhibitor for vascular endothelial growth factor receptor 2 and EGFR on growth and angiogenesis of gliomas expressing EGFRvIII. We used two glioma xenograft models, U87MG cells overexpressing EGFRvIII and short-term cultured primary glioma GBM8 cells with EGFRvIII. ZD6474 inhibited tumor growth and angiogenesis and induced cell apoptosis in various brain gliomas. Moreover, significant inhibition of EGFRvIII-expressing U87MG and GBM8 gliomas was observed compared with their controls. Magnetic resonance imaging analysis using the apparent diffusion coefficient and three-dimensional T2*weighed measurements validated ZD6474 inhibition on tumor growth and angiogenesis in EGFRvIII-expressing GBM8 gliomas. Mechanistically, ZD6474 shows better inhibition of cell growth and survival of U87MG/EGFRvIII, GBM6, and GBM8 cells that express EGFRvIII than U87MG or GBM14 cells that have nondetectable EGFRvIII through attenuation of activated phosphorylation of signal transducer and activator of transcription 3, Akt, and Bcl-X L expression. Albeit in lesser extent, ZD6474 also displays suppressions of U87MG/EGFR and GBM12 cells that overexpress wild-type EGFR. Additionally, ZD6474 inhibits activation of extracellular signal-regulated kinase 1/2 in both types of cells, and expression of a constitutively active phosphoinositide 3-kinases partially rescued ZD6474 inhibition in U87MG/ EGFRvIII cells. Taken together, these data show that ZD6474 significantly inhibited growth and angiogenesis of gliomas expressing EGFRvIII by specifically blocking EGFRvIII-activated signaling mediators, suggesting a potential application of ZD6474 in treatments for glioblastomas that overexpress EGFRvIII. Mol Cancer Ther; 9(4); 929-41. ©2010 AACR.

Important requirements for exogenous dyes or contrast agents in magnetic resonance imaging (MRI) include an effective concentration of paramagnetic or superparamagnetic ions at the target to be imaged. We report the concise synthesis and characterization of several new enantiopure bifunctional derivatives of (α1R,α4R,α7R,α10R)-α1,α4,α7,α10-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTMA) (and their 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) analogues as controls) that can be covalently attached to a contrast agent delivery system using either click or peptide coupling chemistry. Gd complexes of these derivatives can be attached to delivery systems while maintaining optimal water residence time for increased molecular imaging sensitivity. Long chain biotin (LC-biotin) derivatives of the Eu(III) and Gd(III) chelates associated with avidin are used to demonstrate higher efficiencies. Variable-temperature relaxometry, 17O NMR, and nuclear magnetic resonance dispersion (NMRD) spectroscopy used on the complexes and biotin–avidin adducts measure the influence of water residence time and rotational correlation time on constrained and unconstrained systems. The Gd(III)-DOTMA derivative has a shorter water residence time than the Gd(III)-DOTA derivative. Compared to the constrained Gd(III)-DOTA derivatives, the rotationally constrained Gd(III)-DOTMA derivative has ∼40% higher relaxivity at 37 °C, which could increase its sensitivity as an MRI agent as well as reduce the dose of the targeting agent.

No abstract